Kronos Bio, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kronos Bio, Inc. (KRON) is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics targeting deregulated transcription factors to treat cancer and other serious diseases, including MYC-dependent solid tumors, multiple myeloma, HPV-driven tumors, and Sjögren’s disease. The company offers a pipeline of novel product candidates comprising istisociclib (formerly KB-0742), a CDK9 inhibitor in Phase 1/2 clinical trials for MYC-amplified solid tumors such as ovarian cancer; KB-9558, a p300 KAT inhibitor targeting the IRF4 transcriptional regulatory network in preclinical development for multiple myeloma and HPV-driven tumors; and KB-7898, a p300 KAT inhibitor in preclinical development for Sjögren’s disease. Kronos Bio, founded in 2017 and headquartered in San Mateo, California, primarily operates in the United States within the biotechnology sector, serving patients with high-unmet-need oncology and immunology indications. In mid-2025, the company undergoes acquisition by Concentra Biosciences, LLC, for $0.57 per share in cash plus contingent value rights tied to pipeline asset dispositions and cost savings, following a definitive merger agreement announced on May 1, 2025; subsequently in October 2025, Ignota Labs acquires its clinical-stage assets, including istisociclib. As of June 2025, Kronos Bio operates as a subsidiary of Concentra Biosciences with approximately 10 employees.
Kronos Bio Completes Sale to Concentra Biosciences
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRON
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
Kronos Bio Announces CEO Transition and Reduction in Force
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
Kronos Bio downgraded to Neutral from Overweight at Piper Sandler
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
Kronos Bio Announces Participation in Medical and Investor Conferences in September
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON)
Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy?